{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:08:45Z","timestamp":1785434925410,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jconrel.2020.12.031","type":"journal-article","created":{"date-parts":[[2020,12,20]],"date-time":"2020-12-20T10:13:35Z","timestamp":1608459215000},"page":"529-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2"],"prefix":"10.1016","volume":"330","author":[{"given":"Kyung Soo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Bazzill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejin","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutaek","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz J.","family":"Ochyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne A.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia C.","family":"LaBranche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.12.031_bb0005","doi-asserted-by":"crossref","first-page":"117956","DOI":"10.1016\/j.lfs.2020.117956","article-title":"Vaccination strategies to combat novel corona virus SARS-CoV-2","volume":"256","author":"Pandey","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le Thanh","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: what you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2051013613480144","article-title":"Working together: interactions between vaccine antigens and adjuvants","volume":"1","author":"Fox","year":"2013","journal-title":"Ther. Adv. Vaccin."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1403","article-title":"Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens","volume":"9","author":"Fan","year":"2017","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0030","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0035","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1021\/acs.molpharmaceut.9b00860","article-title":"Rational design of PLGA nanoparticle vaccine delivery systems to improve immune responses","volume":"16","author":"Gu","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0040","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41467-018-03473-9","article-title":"Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer","volume":"9","author":"Nam","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22050857","article-title":"Applications of gold nanoparticles in nanomedicine: recent advances in vaccines","volume":"22","author":"Carabineiro","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0050","doi-asserted-by":"crossref","first-page":"12148","DOI":"10.1021\/acsnano.9b06691","article-title":"Positron emission tomography-guided photodynamic therapy with biodegradable mesoporous silica nanoparticles for personalized cancer immunotherapy","volume":"13","author":"Xu","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4462","article-title":"The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency","volume":"6","author":"Hong","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-based vaccines against respiratory viruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","article-title":"Vaccine delivery using nanoparticles","volume":"3","author":"Gregory","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0075","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1038\/s41598-020-65059-0","article-title":"Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines\/immunoprophylaxis in animals including transchromosomic bovines","volume":"10","author":"Mucker","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113605","article-title":"DNA vaccines-how far from clinical use?","volume":"19","author":"Hobernik","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.08.004","article-title":"DNA-loaded cationic liposomes efficiently function as a vaccine against malarial proteins","volume":"7","author":"Fotoran","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0090","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0095","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/312763a0","article-title":"The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus","volume":"312","author":"Dalgleish","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature\u2019s pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0110","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.cell.2015.11.056","article-title":"Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes","volume":"163","author":"de Taeye","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nm.3565","article-title":"Early development of broadly neutralizing antibodies in HIV-1-infected infants","volume":"20","author":"Goo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0135","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0140","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0145","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0150","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0155","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1128\/JVI.03451-14","article-title":"Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env","volume":"89","author":"Georgiev","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0160","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0165","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.1021\/acs.nanolett.8b03601","article-title":"Interrogation of antigen display on individual vaccine nanoparticles for achieving neutralizing antibody responses against hepatitis C virus","volume":"18","author":"Bazzill","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.nano.2018.11.005","article-title":"Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses","volume":"18","author":"Bazzill","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0175","doi-asserted-by":"crossref","first-page":"11087","DOI":"10.1021\/acsnano.9b03660","article-title":"Multilamellar vaccine particle elicits potent immune activation with protein antigens and protects mice against Ebola virus infection","volume":"13","author":"Fan","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0180","series-title":"HIV Protocols","first-page":"395","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","author":"Montefiori","year":"2009"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0190","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2147\/IJN.S125866","article-title":"Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens","volume":"12","author":"Gao","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0195","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2006.10.032","article-title":"A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120","volume":"360","author":"Beddows","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2020.12.031_bb0200","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/428406","article-title":"Lessons from failure\u2014preparing for future HIV-1 vaccine efficacy trials","volume":"191","author":"Graham","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01779-17","article-title":"Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates","volume":"92","author":"Qualls","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2020.12.031_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920307550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:58:34Z","timestamp":1759161514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920307550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":42,"alternative-id":["S0168365920307550"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}